Literature DB >> 25597888

Simultaneous quantification of chrysophanol and physcion in rat plasma by ultra fast liquid chromatography-tandem mass spectrometry and application of the technique to comparative pharmacokinetic studies of Radix et Rhei Rhizoma extract alone and Dahuang Fuzi Decoction.

Xiao Liu1, Huan Li2, Li Wu3, Jiangwa Xing4, Yanhong Poh5, Hao Cai3, Bao Chang Cai6.   

Abstract

Most herbal medicines are prescribed in combination based on the theory of TCM to obtain synergistic effects or diminish the possible adverse reactions. Compatibility refers to the combination of two or more herbs based on the clinical settings and the properties of herbs. Chrysophanol and physcion are the main effective compounds in Radix et Rhizoma Rhei and Dahuang Fuzi Decoction which is the combination of Radix et Rhizoma Rhei, Radix Aconiti Lateralis Praeparata and Radix et Rhizoma Asari. However, chrysophanol and physcion are difficult to detect in vivo because of their low concentration and interference from endogenous compounds. The aim of this study is to develop a rapid, specific and sensitive ultra high performance liquid chromatography-triple quadrupole tandem mass method to simultaneously quantify chrysophanol and physcion in rat plasma, in order to better understand the pharmacokinetics and compatibility mechanism of Dahuang Fuzi Decoction for the first time. Multiple reaction monitoring (MRM) mode was applied for the quantitation at [M-H](-)m/z 253.0→m/z 225.1 for chrysophanol, [M-H](-) for m/z 283.1→m/z 240.0 physcion and [M-H](-)m/z 239.0→m/z 211.0 for IS. The analytes were separated on an Agilent Eclipse plus C18 column (100mm×2.1mm, 1.8μm) column within a total running time of 6.5min using a mixture of 3mM ammonium acetate in water and methanol (95:5, v/v) with a time program flow gradient according to the "plus gradient chromatography" theory. The inclusion of the ammonium acetate in the UFLC mobile phase dramatically improved the detection limit of the tested compounds and decreased the interference by matrix effects, which have been referred to as "LC-electrolyte effects". Finally, we demonstrated the application of a validated method in a comparative pharmacokinetic study of rats receiving an oral dose of Dahuang Fuzi Decoction or Radix et Rhei Rhizoma, the monarch drug in the prescription. Pharmacokinetic parameters showed significant difference between the two groups. The achieved comparative pharmacokinetic results were helpful to clarify the combination mechanism of Dahuang Fuzi Decoction.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Chrysophanol; MRM; Pharmacokinetics; Physcion; UFLC–MS/MS

Mesh:

Substances:

Year:  2014        PMID: 25597888     DOI: 10.1016/j.jchromb.2014.11.025

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia.

Authors:  Honglei Tu; Bo Lei; Shan Meng; Hailing Liu; Yongchang Wei; Aili He; Wanggang Zhang; Fuling Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-21       Impact factor: 2.629

Review 2.  Chrysophanol: A Natural Anthraquinone with Multifaceted Biotherapeutic Potential.

Authors:  Mohd Aslam Yusuf; Brahma N Singh; Surya Sudheer; Ravindra N Kharwar; Saba Siddiqui; Ahmed M Abdel-Azeem; Leonardo Fernandes Fraceto; Kavya Dashora; Vijai K Gupta
Journal:  Biomolecules       Date:  2019-02-18

Review 3.  Pharmacokinetics of Anthraquinones from Medicinal Plants.

Authors:  Dongpeng Wang; Xian-He Wang; Xiongjie Yu; Fengjun Cao; Xiaojun Cai; Ping Chen; Minglun Li; Yibin Feng; Hongliang Li; Xuanbin Wang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

4.  The Network Pharmacology Study of Dahuang Fuzi Decoction for Treating Incomplete Intestinal Obstruction.

Authors:  Jun-Feng Guo; Yu-Ting Zhao; Quan-Yu Du; Yuan Ren; Yan Wang; Zhen-Xing Wang; Wei Jin
Journal:  Biomed Res Int       Date:  2022-04-28       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.